Preliminary evidence suggests that postoperative cognitive dysfunction (POCD) is common after lung transplantation. The impact of POCD on clinical outcomes has yet to be studied. The association between POCD and longer-term survival was therefore Declines in Executive Function tended to be predictive of worse survival. These preliminary findings suggest that postoperative neurocognition is predictive of subsequent mortality among lung transplant recipients. Further research is needed to confirm these findings in a larger sample and to examine mechanisms responsible for this relationship.
| INTRODUCTION
Lung transplantation continues to be the only remaining option for many individuals with advanced pulmonary disease.
1 After the implementation of the lung allocation score in 2005, lung recipients have become increasingly older and sicker, 2 with a median age of transplantation approaching 60 years. 3 Despite changes in recipient characteristics and perioperative management strategies, posttransplantation survival has remained constant at a median of 6 years, more than 50% lower than the rate for other solid organ transplant groups, 4 and few medical characteristics have proven prognostic of long-term risk. 5 Emerging research suggests that postoperative cognitive dysfunction (POCD) is common after lung transplantation, occurring in more than half of recipients. [6] [7] [8] POCD may have important clinical implications, as poorer neurocognitive function has been associated with worse quality of life, greater risk of medication nonadherence, 9, 10 and poorer clinical outcomes in other patient populations. [11] [12] [13] [14] However, to our knowledge, no studies have examined the association between POCD and clinical outcomes among lung transplant recipients. We therefore examined the association between POCD and mortality among participants from a previously published randomized trial of coping skills training. 15 
| METHODS
The present analyses were based on data collected as part of the 
| Clinical and demographic characteristics
Demographic data were self-reported by participants at the time of their neurocognitive testing battery. Data on forced expiratory volume (FEV 1 ), number of rejection episodes, and other medical data were obtained from participants' medical records.
| Neurobehavioral assessments
Participants completed a battery of neurocognitive tests approximately 6 months after transplantation (mean = 6 months [SD = 0.14 month]). 
| Statistical analyses
Neurocognitive predictors of posttransplantation survival were examined by using separate Cox proportional hazards models (SAS 9.4 and R 3.4.1). To control for potential background and medical factors that would also influence mortality, we included native disease (cystic fibrosis [CF] vs non-CF), FEV 1 , total numbers of rejection episodes during the first 6 months after transplantation, and years of education.
Because native disease and age are confounded, we chose to model native disease instead of age as a covariate. In addition, because our model had limited power due to a small sample size, we chose to model native disease as CF versus non-CF to account for both native disease differences and age differences in the most parsimonious manner. Results were unchanged if both age and native disease were included as independent predictors.
Neurocognitive function subtests were combined to minimize the number of statistical tests in the present analysis. Principal axis factor analysis was used to combine the information from the 13 individ- COWA, and Animal Naming Test. These composites were then used as the predictors of interest in separate proportional hazards regression analyses due to their collinearity. In addition, to minimize the potential impact of our factor groupings on our mortality analyses,
we also examined the association between an overall composite of neurocognitive functioning composed of all subtests. All continuous predictors, including our neurocognitive predictors, were scaled by using the interquartile range (IQR), which allows for the comparison of individuals at the 75th and 25th percentiles of a given predictor variable. In a final set of exploratory analyses, we examined differences in survival between individuals whose neurocognition remained stable or improved from pretransplantation assessments (demographically corrected t-score mean change ≥0) compared with those whose performance declined (demographically corrected t-score mean change <0). Because there is no standardized definition for "neurocognitive decline," 26-28 these analyses are presented only to characterize the magnitude of association between worsening neurocognition and subsequent mortality.
| RESULTS

| Sample characteristics
Eighty-seven participants from Duke were alive 6 months after transplantation, among whom 49 completed cognitive testing (Table 1) . Participants who completed testing did not appear to differ appreciably from the remainder of the cohort on any relevant demographic or medical characteristics, including native disease (P = .506), age (P = .912), sex (P = .686), years of education (P = .869), type of transplant (P = .164), number of rejection episodes (P = .661), duration of transplant hospitalization (P = .426), pretransplantation functional capacity (P = .178), or 6-month FEV 1 (P = .900).
T 
| Neurocognitive test performance
As shown in Table 2 , demographically corrected levels of neurocognitive test performance revealed that 10 (20%) individuals exhibited at least 1 impairment on the test battery at their 6-month assessment, although performance across the cohort was generally in the average range (ie, t-scores between 43 and 57). Principal axis factor analysis revealed 3
underlying factors within our test battery: Processing Speed, Executive Function, and Verbal Memory (Table 3) . Unit-weighted composite measures were subsequently created for each cognitive factor, which were used as the predictors of interest in our survival models described next. 
| Neurocognition and mortality
| Neurocognitive decline and mortality
To examine the relationship between changes in neurocognition after transplantation and subsequent mortality, we conducted an additional set of analyses in which individuals were grouped into those whose cognitive performance either improved or remained stable compared 
| DISCUSSION
Results from the present analyses suggest that poorer neurocognitive performance after lung transplantation is predictive of subsequent survival, after accounting for other medical and background characteristics. These findings extend previous findings suggesting that POCD is common among lung transplant recipients and may be associated with worse short-term outcomes by demonstrating that POCD Values in bold denote loading on a given factor.
T A B L E 3 Neurocognitive factor structure following Promax rotation may predict long-term risk after transplantation, similar to associations observed in other medical populations.
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Previous studies have suggested that POCD is common after lung transplantation, occurring in an estimated 50-67% of recipients, depending, in part, on the timing and modality of assessment. [6] [7] [8] For example, we previously demonstrated that impairments are common within the first month after transplantation and may persist in some patients when assessed again approximately 3 months postoperatively.
7
Impairments appear to occur most commonly on tests of Executive Function, 6, 7 which is thought to reflect the integrity of brain regions in the prefrontal cortex and subcortical connections. 30 Interestingly, impairments in tests associated with frontal lobe functioning, including the Stroop, Digit Span, and COWA, were most predictive of subsequent mortality, consistent with prior studies. [11] [12] [13] [14] Although we previously reported that neurocognitive performance associated before transplantation was associated with increased mortality, 31 to our knowledge no studies have examined this association after transplantation, after which many individuals experience neurocognitive decline.
There are several plausible mechanisms by which neurocognition may be associated with clinical outcomes. Among solid organ transplant recipients, adherence to immunosuppression medications is critical to survival and has been strongly associated with mortality.
32,33
Although no studies have examined the association between neurocognition and adherence in lung transplant recipients, numerous epidemiological studies in other health populations suggest that impairments 
| Limitations
These preliminary findings must be viewed with caution. First, the study cohort was relatively small and larger prospective studies are needed to verify the observed associations. Second, neurocognitive performance was only collected at 1 time point after transplantation.
Nevertheless, our neurocognitive test battery was comprehensive and assessed multiple domains of functioning, which we consider a strength despite only 1 assessment time point. Third, future studies using neuroimaging methods are needed to better characterize the mechanisms underlying POCD after transplantation, as noted earlier. In addition, future studies more comprehensively assessing potential behavioral mechanisms are also important, as behavioral compliance characteristics (eg, medication adherence and lifestyle practices) or additional physiological processes may also explain the observed associations.
| Conclusions
Our results suggest that poorer neurocognition 6 months after transplantation is a marker of long-term risk and should be examined when Analyses included all participants but did not correct for multiple testing.
T A B L E 5 Explanatory analyses of individual neurocognitive subtests from separate Cox proportional hazards models possible among transplant recipients. If the present findings are replicated, it may indicate a need to identify and more closely manage individuals exhibiting neurocognitive impairment after transplantation.
In addition, prospective studies examining neuroimaging mechanisms of POCD are needed to identify risk factors and possible treatment targets to mitigate POCD risk.
